E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Ulcerative colitis |
Ulcerozni kolitis |
|
E.1.1.1 | Medical condition in easily understood language |
Inflammatory bowel disease - ulcerative colitis |
Kronična vnetna črevesna bolezen - ulcerozni kolitis. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare endoscopic outcomes of high dose induction/maintenance golimumab therapy (200 mg sc, followed by 100 mg sc at week 2 and then 100 mg sc q4wk) with current practice (50 mg in patients >80kg BW and 100 mg sc in patients with ≥ 80kg BW q4wk) in moderate to severe ulcerative colitis. |
Ugotoviti ali zgodnja optimizacija odmerka golimumaba na 100 mg sc/4 tedne (ne glede na telesno maso) vpliva na endoskopsko remisijo pri pacientih z aktivnim ulceroznim kolitisom v primerjavi s trenutnim odmerjanjem, kjer se pri pacientih z >80 kg TT odmerek dvigne iz 50 mg sc/4 tedne na 100 mg sc/4 tedne samo ob nezadostnem kliničnem odgovoru. Paciente z ≥80 kg TT se že takoj začne zdraviti z odmerkom 100 mg sc/4 tedne. |
|
E.2.2 | Secondary objectives of the trial |
1) To compare clinical outcomes of high dose induction/maintenance golimumab therapy (200 mg sc, followed by 100 mg sc at week 2 and then 100 mg sc q4wk) with current practice (50 mg in patients >80kg BW and 100 mg sc in patients with ≥ 80kg BW q4wk) in moderate to severe ulcerative colitis.
2) To assess if development of anti-golimumab antibodies affects endoscopic outcomes in patients treated with golimumab.
3) To assess if development of anti-golimumab antibodies affects clinical outcomes in patients treated with golimumab.
4) Measurement of physical, social, and emotional status with The Short Inflammatory Bowel Disease Questionnaire.
5) Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.0.
|
1) Ugotoviti ali zgodnja optimizacija odmerka golimumaba na 100 mg sc/4 tedne (ne glede na telesno maso) vpliva na klinično remisijo pri pacientih z aktivnim ulceroznim kolitisom v primerjavi s trenutnim odmerjanjem, kjer se pri pacientih z >80 kg TT odmerek dvigne iz 50 mg sc/4 tedne na 100 mg sc/4 tedne samo ob nezadostnem kliničnem odgovoru. Paciente z ≥80 kg TT se že takoj zažne zdraviti z odmerkom 100 mg sc/4 tedne.
2) Ugotoviti ali pojav anti-golimumabnih protiteles vpliva na endoskopsko remisijo pri pacientih zdravljenih z golimumabom.
3) Ugotoviti ali pojav anti-golimumabnih protiteles vpliva na klinično remisijo pri pacientih zdravljenih z golimumabom.
4) Oceniti kvaliteto življenja pacientov zdravljenih z golimumabom.
5) Oceniti varnost in incidenco stranskih učinkov povezanih z zdravljenjem.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Histologicaly confirmed ulcerative colitis
2) age <18 years old
|
1) Histološko potrjen ulcerozni kolitis
2) Starost >18 let
|
|
E.4 | Principal exclusion criteria |
1) History of allergic reactions to sorbitol (E420), L-histidine, L-histidine monohydrochloride monohydrate, polysorbate80, water for injections.
2) Active tuberculosis or other opportunistic bacterial, viral and fungal infections.
3) History of moderate to severe heart failure (NYHA III/IV), and potential risk of congestive heart failure .
4) Pregnancy.
|
1) Preobčutljivost na učinkovino golimumab ali katerokoli pomožno snov (sorbitol (E420), L-histidin, L-histidinijev klorid monohidrat, Polisorbat 80, voda za injekcije).
2) Aktivna tuberkuloza ali druge hude okužbe, kot so sepsa in oportunistične okužbe.
3) Zmerno ali hudo srčno popuščanje (NYHA III ali IV).
4) Nosečnost.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
1) Endoscopic outcome: Number of participants with mucosal healing at week 14 and week 50 on flexible rectosigmoidoscopy (recorded and assessed centrally by blinded reader if possible). Mucosal healing is defined as Mayo endoscopic score 0 or 1.
|
1) Endoskopski izhod: Oceniti število bolnikov v endoskopski remisiji v 14. in 50. tednu. Endoskopska remisija bo ocenjena s fleksibilno rektosigmoidoskopijo. Preiskava bo posneta, če bo le možno jo bo pregledal on ocenil neodvisni endoskopist, ki ne bo imel podatkov o pacientu. Remisija je definirana kot Mayo endoscopic score 0 ali 1.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1) Endoscopic outcome: Number of participants with mucosal healing at week 14 and week 50
|
1) Endoskopski izhod: Oceniti število bolnikov v endoskopski remisiji v 14. in 50. tednu. |
|
E.5.2 | Secondary end point(s) |
1) Clinical outcome: Number of participants in clinical remission at week 14, week 26, week 38 and week 50. Clinical remission is defined as PRO-2 (Patient-Reported Outcome) score 0 (no rectal bleeding and no diarrhea/altered bowel habit).
2) Association of golimumab through levels and Anti-golimumab antibodies development on endoscopic and clinical outcome.
2a) Measurement of golimumab through levels. Blood withdrawals will be preformed at prespecified time points in all patients: week 0, week 2, week 4, week 6, week 10, week 14, week 26, week 38 and week 50.
2b) Measurement of Anti-golimumab antibodies development. Blood withdrawals will be preformed at prespecified time points in all patients: week 2, week 4, week 6, week 10, week 14, week 26, week 38 and week 50.
3) Measurement of physical, social, and emotional status with The Short Inflammatory Bowel Disease Questionnaire.
The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) is a health-related quality of life (HRQoL) tool measuring physical, social, and emotional status (score 10-70, poor to good HRQoL). The questionnaire will be answered at week 0, week 6, week 14, week 26, week 38, week 50.
4) Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.0 - Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0.
|
1) Ocena klinične remisije (brez zagona bolezni): Število bolnikov v klinični remisiji v 14., 26., 38. in 50. tednu. Klinična remisija je definirana kot PRO-2 = 0 točk (brez proktoragije ali driske/spremembe v odvajanju blata.
2) Povezava serumske koncentracije golimumaba pred aplikacijo in povezava pojava proti-golimumabnih protiteles z endoskopskim in kliničnim izhodom.
2a) Izmeritev serumske koncentracije golimumaba pred aplikacijo pri vseh pacientih v naprej določenih intervalih: teden 0, 2, 4, 6, 10, 14, 26, 38 in 50.
2b) Izmeriti prisotnost proti-golimumabnih protiteles pri vseh pacientih v naprej določenih intervalih: teden 0, 2, 4, 6, 10, 14, 26, 38 in 50.
3) Ocena kvalitete življenja (The Short Inflammatory Bowel Disease Questionnaire (SIBDQ)). S tem vprašalnikom bomo ocenili fizični, socialni in emocionalni status. Pacienti bodo odgovarjali na vprašalnik v tednu 0, 6, 14, 26, 38 in 50.
4) Incidenca nezaželenih sopojavov, ki so posledica zdravljenja z golimumabom (CTCAE v4.0) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) Clinical outcome: Number of participants in clinical remission at week 14, week 26, week 38 and week 50.
2a and b) Golimumab trough level and antibody measurements: week 0, week 2, week 4, week 6, week 10, week 14, week 26, week 38 and week 50.
3) The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) will be answered at week 0, week 6, week 14, week 26, week 38, week 50.
4) Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.0. (anytime during treatment) |
1) Klinični izhod: Število bolnikov v remisiji v 14., 26., 38. in 50. tednu.
2a in b) Serumska koncentracija golimumaba pred aplikacijo in prisotnost protiteles proti golimumabu: teden 0, 2, 4, 6, 10, 14, 26, 38 in 50.
3) Ocena kvalitete življenja (The Short Inflammatory Bowel Disease Questionnaire (SIBDQ)). Pacienti bodo odgovarjali na vprašalnik v tednu 0, 6, 14, 26, 38 in 50.
4) Incidenca nezaželenih sopojavov, ki so posledica zdravljenja z golimumabom (CTCAE v4.0) (stalno spremljanje) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Drugačen odmerek golimumaba. |
Different dose of golimumab. |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS. |
Zadnji obisk pacienta. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |